Form 4: TELA Bio CEO Boosts Equity, Manages Tax Obligations

TELA Bio's CEO, Antony Koblish, acquired significant equity awards and simultaneously sold shares to cover tax liabilities from RSU vesting.

Summary

• Antony Koblish, Chief Executive Officer and Director of TELA Bio, Inc., reported recent equity transactions.
• On February 20, 2026, Mr. Koblish was granted 176,000 Restricted Stock Units (RSUs) with a vesting schedule of four equal annual installments beginning February 20, 2027.
• Concurrently, he received a grant of 261,000 stock options with an exercise price of $0.717, vesting 25% on February 20, 2027, and the remainder monthly over 36 months.
• Mr. Koblish also disposed of common stock shares to satisfy tax withholding obligations related to the vesting of previously granted RSUs.
• These dispositions included 12,494 shares on February 21, 2026, at $0.7174 per share, 11,631 shares on February 23, 2026, at $0.766 per share, and 3,900 shares on February 24, 2026, at $0.7852 per share.
• Following these transactions, Mr. Koblish's direct beneficial ownership of common stock stands at 586,210 shares, in addition to the newly acquired unvested RSUs and stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the significant grant of new equity awards to the CEO demonstrates continued commitment and aligns management's long-term interests with shareholders, despite the routine tax-related share disposals.

Positives

• The grant of 176,000 new Restricted Stock Units (RSUs) to the CEO demonstrates continued confidence in the company and aligns his long-term interests with shareholder value.
• The acquisition of 261,000 new stock options provides additional performance incentives for the CEO.

Negatives

• A total of 28,025 shares of common stock were disposed of to cover tax liabilities, representing a reduction in direct common stock holdings.

Future Outlook

The newly granted Restricted Stock Units (RSUs) will vest in four equal annual installments beginning on February 20, 2027, subject to the CEO's continuous service. The newly granted stock options will vest 25% on February 20, 2027, with the remaining 75% vesting in equal monthly installments over the subsequent 36 calendar months, also contingent on continuous service.

Industry Context

StockSavvy.ai notes that the granting of equity awards like RSUs and stock options is a standard practice in executive compensation across various industries, designed to align management's long-term incentives with shareholder interests. The subsequent sale of shares to cover tax obligations upon vesting is also a routine and expected event for executives receiving such compensation.

Stakeholder Impact

• Shareholders: The significant grant of new equity awards to the CEO enhances the alignment of his long-term financial interests with the company's performance and shareholder value.
• Employees: The CEO's continued receipt of substantial equity compensation may signal stability and confidence in the company's future direction.

Next Steps

• Vesting of 176,000 Restricted Stock Units (RSUs) in four equal annual installments beginning February 20, 2027.
• Vesting of 261,000 stock options, with 25% vesting on February 20, 2027, and the remainder monthly over 36 months.

Key Dates

Keywords

TELA Bio, Antony Koblish, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant